These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 5976205)
1. A double-blind evaluation of S.D. 25 in the treatment of Parkinson's disease. Strang RR Curr Med Drugs; 1966 Dec; 7(4):20-6. PubMed ID: 5976205 [No Abstract] [Full Text] [Related]
2. Clinical evaluation of biperiden in Parkinson's disease. Strang RR Dis Nerv Syst; 1967 Mar; 28(3):191-3. PubMed ID: 5335879 [No Abstract] [Full Text] [Related]
3. [Clinical aspects and drug therapy of Parkinson's syndrome]. Mumenthaler M Schweiz Med Wochenschr; 1966 Apr; 96(15):479-84. PubMed ID: 4862148 [No Abstract] [Full Text] [Related]
4. [L-Dopa therapy in Parkinson's disease. A double-blind study]. Worm-Petersen J; Dupont E; Mikkelsen B Ugeskr Laeger; 1971 Nov; 133(47):2321-6. PubMed ID: 4944651 [No Abstract] [Full Text] [Related]
5. [The therapeutic effectiveness of amantadine (midantan) in parkinsonism syndromes]. Kiseleva AM; Zlydnikov DM; Mazhinskaia VP; Lebedeva VK; Zakharova NG Zh Nevropatol Psikhiatr Im S S Korsakova; 1973; 73(4):530-4. PubMed ID: 4705408 [No Abstract] [Full Text] [Related]
6. [Treatment of the Parkinson syndrome with amantadine]. Hartmann-von Monakow K Schweiz Med Wochenschr; 1971 Dec; 101(48):1736-9. PubMed ID: 5140093 [No Abstract] [Full Text] [Related]
8. The clinical use of levodopa in the treatment of Parkinson's disease. McDowell FH; Markham CH; Lee JE; Treciokas LJ; Ansel RD Contemp Neurol Ser; 1971; 8():175-201. PubMed ID: 4950056 [No Abstract] [Full Text] [Related]
9. [Study of L-dopa treatment and its principal side effects in aged subjects]. Antonini F; Baroni A; Bucalossi A; Roveyaz L Gerontol Clin (Basel); 1972; 14(5):297-309. PubMed ID: 4144357 [No Abstract] [Full Text] [Related]
10. The Graeme Robertson memorial lecture, 1983. The long-term prognosis of Parkinson's disease. Selby G Clin Exp Neurol; 1984; 20():1-25. PubMed ID: 6391761 [TBL] [Abstract][Full Text] [Related]
11. Cerebrospinal fluid N-acetyl neuraminic acid in Parkinson's disease, before and after L-dopa therapy. Lipman IJ; Papadopoulos NM Dis Nerv Syst; 1973 Jan; 34(1):59-62. PubMed ID: 4709194 [No Abstract] [Full Text] [Related]
16. [Psychic manifestations during treatment of Parkinson's disease with L-dopa]. Bonduelle M Rev Neurol (Paris); 1970 Feb; 122(2):140. PubMed ID: 5517897 [No Abstract] [Full Text] [Related]
17. [Use of the preparation L-dopa in parkinsonism]. Proniv DI; Sirotina OS; Bukhovtsev PP; Mis'kiv IaI Vrach Delo; 1976 Jan; (1):113-6. PubMed ID: 1246837 [No Abstract] [Full Text] [Related]
18. A double-blind evaluation of lysivane in the treatment of Parkinson's disease. Strang RR Br J Clin Pract; 1966 May; 20(5):249-51. PubMed ID: 5326485 [No Abstract] [Full Text] [Related]
19. Abnormal mouth-movements and oral damage associated with L-DOPA treatment. Sacks OW; Ross SJ; DePaola DP; Kohl MS Ann Dent; 1970; 29(4):130-44. PubMed ID: 5275661 [No Abstract] [Full Text] [Related]
20. [The Rorschach test in parkinsonian patients. Its course during treatment with L dopa. Its prognostic value]. Sevilla M; Vernet JP; Becle J; Darcourt G Ann Med Psychol (Paris); 1973 May; 1(5):577-608. PubMed ID: 4761931 [No Abstract] [Full Text] [Related] [Next] [New Search]